PMC:7271924 / 28556-30124 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PMC-OGER-BB

LitCovid-PubTator

{"project":"LitCovid-PubTator","denotations":[{"id":"750","span":{"begin":0,"end":11},"obj":"Gene"},{"id":"751","span":{"begin":1350,"end":1354},"obj":"Gene"},{"id":"752","span":{"begin":1359,"end":1363},"obj":"Gene"},{"id":"753","span":{"begin":852,"end":860},"obj":"Gene"},{"id":"754","span":{"begin":181,"end":194},"obj":"Species"},{"id":"755","span":{"begin":346,"end":356},"obj":"Species"},{"id":"756","span":{"begin":534,"end":542},"obj":"Species"},{"id":"757","span":{"begin":803,"end":811},"obj":"Species"},{"id":"758","span":{"begin":258,"end":280},"obj":"Disease"},{"id":"759","span":{"begin":478,"end":487},"obj":"Disease"},{"id":"760","span":{"begin":562,"end":581},"obj":"Disease"},{"id":"761","span":{"begin":1123,"end":1132},"obj":"Disease"},{"id":"762","span":{"begin":1185,"end":1193},"obj":"Disease"},{"id":"763","span":{"begin":1546,"end":1554},"obj":"Disease"}],"attributes":[{"id":"A750","pred":"tao:has_database_id","subj":"750","obj":"Gene:280846"},{"id":"A751","pred":"tao:has_database_id","subj":"751","obj":"Gene:59272"},{"id":"A752","pred":"tao:has_database_id","subj":"752","obj":"Gene:6383"},{"id":"A753","pred":"tao:has_database_id","subj":"753","obj":"Gene:43740571"},{"id":"A754","pred":"tao:has_database_id","subj":"754","obj":"Tax:11118"},{"id":"A755","pred":"tao:has_database_id","subj":"755","obj":"Tax:2697049"},{"id":"A756","pred":"tao:has_database_id","subj":"756","obj":"Tax:694009"},{"id":"A757","pred":"tao:has_database_id","subj":"757","obj":"Tax:694009"},{"id":"A758","pred":"tao:has_database_id","subj":"758","obj":"MESH:D018352"},{"id":"A759","pred":"tao:has_database_id","subj":"759","obj":"MESH:D007239"},{"id":"A760","pred":"tao:has_database_id","subj":"760","obj":"MESH:C000657245"},{"id":"A761","pred":"tao:has_database_id","subj":"761","obj":"MESH:D007239"},{"id":"A762","pred":"tao:has_database_id","subj":"762","obj":"MESH:C000657245"},{"id":"A763","pred":"tao:has_database_id","subj":"763","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Lactoferrin clearly has immunological benefits, as well as having an important antibacterial and antiviral role. Because it is known to interfere with some of the receptors used by coronaviruses, it may contribute usefully to the prevention and treatment of coronavirus infections. Figure 6 shows a possible scheme on how LF might interfere with SARS-CoV-2 binding. The binding of LF to HSPGs prevents the first contact between virus and host cells and thus prevents subsequent infection (99). HSPGs themselves are not sufficient for SARS-CoV entry. However, in SARS-CoV infections, the HSPGs play an important role in the process of cell entry (99). The anchoring sites provided by HSPGs permit initial contact between the virus and host cells and the concentration of virus particles on cell surface. SARS-CoV bound to HSPGs then rolls onto the cell membrane and scans for specific entry receptors, which leads to subsequent cell entry (99). LF enhances natural killer cell activity and stimulates neutrophil aggregation and adhesion in immune defense (135) and can restrict the entry of the virus into host cells during infection. We suggest that this process might be the same for COVID-19 (see Figure 6 for a visual representation), thereby offering useful strategies for prevention and treatment. Currently, there is also a renewed interest in ACE2 and HSPG blocking, as discussed in the introduction (5–8). LF may therefore be an excellent supplement to take, not only as a contribution to prevention but perhaps as a therapy in the event COVID-19 is diagnosed."}

LitCovid-PD-FMA-UBERON

LitCovid-PD-MONDO

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T104","span":{"begin":270,"end":280},"obj":"Disease"},{"id":"T105","span":{"begin":346,"end":354},"obj":"Disease"},{"id":"T106","span":{"begin":478,"end":487},"obj":"Disease"},{"id":"T107","span":{"begin":534,"end":542},"obj":"Disease"},{"id":"T108","span":{"begin":562,"end":570},"obj":"Disease"},{"id":"T109","span":{"begin":571,"end":581},"obj":"Disease"},{"id":"T110","span":{"begin":803,"end":811},"obj":"Disease"},{"id":"T111","span":{"begin":1123,"end":1132},"obj":"Disease"},{"id":"T112","span":{"begin":1185,"end":1193},"obj":"Disease"},{"id":"T113","span":{"begin":1546,"end":1554},"obj":"Disease"}],"attributes":[{"id":"A104","pred":"mondo_id","subj":"T104","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A105","pred":"mondo_id","subj":"T105","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A106","pred":"mondo_id","subj":"T106","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A107","pred":"mondo_id","subj":"T107","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A108","pred":"mondo_id","subj":"T108","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A109","pred":"mondo_id","subj":"T109","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A110","pred":"mondo_id","subj":"T110","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A111","pred":"mondo_id","subj":"T111","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A112","pred":"mondo_id","subj":"T112","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A113","pred":"mondo_id","subj":"T113","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Lactoferrin clearly has immunological benefits, as well as having an important antibacterial and antiviral role. Because it is known to interfere with some of the receptors used by coronaviruses, it may contribute usefully to the prevention and treatment of coronavirus infections. Figure 6 shows a possible scheme on how LF might interfere with SARS-CoV-2 binding. The binding of LF to HSPGs prevents the first contact between virus and host cells and thus prevents subsequent infection (99). HSPGs themselves are not sufficient for SARS-CoV entry. However, in SARS-CoV infections, the HSPGs play an important role in the process of cell entry (99). The anchoring sites provided by HSPGs permit initial contact between the virus and host cells and the concentration of virus particles on cell surface. SARS-CoV bound to HSPGs then rolls onto the cell membrane and scans for specific entry receptors, which leads to subsequent cell entry (99). LF enhances natural killer cell activity and stimulates neutrophil aggregation and adhesion in immune defense (135) and can restrict the entry of the virus into host cells during infection. We suggest that this process might be the same for COVID-19 (see Figure 6 for a visual representation), thereby offering useful strategies for prevention and treatment. Currently, there is also a renewed interest in ACE2 and HSPG blocking, as discussed in the introduction (5–8). LF may therefore be an excellent supplement to take, not only as a contribution to prevention but perhaps as a therapy in the event COVID-19 is diagnosed."}

LitCovid-PD-CLO

LitCovid-PD-CHEBI

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T354","span":{"begin":97,"end":106},"obj":"Chemical"},{"id":"T355","span":{"begin":322,"end":324},"obj":"Chemical"},{"id":"T356","span":{"begin":381,"end":383},"obj":"Chemical"},{"id":"T357","span":{"begin":944,"end":946},"obj":"Chemical"},{"id":"T358","span":{"begin":1414,"end":1416},"obj":"Chemical"}],"attributes":[{"id":"A354","pred":"chebi_id","subj":"T354","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A355","pred":"chebi_id","subj":"T355","obj":"http://purl.obolibrary.org/obo/CHEBI_73585"},{"id":"A356","pred":"chebi_id","subj":"T356","obj":"http://purl.obolibrary.org/obo/CHEBI_73585"},{"id":"A357","pred":"chebi_id","subj":"T357","obj":"http://purl.obolibrary.org/obo/CHEBI_73585"},{"id":"A358","pred":"chebi_id","subj":"T358","obj":"http://purl.obolibrary.org/obo/CHEBI_73585"}],"text":"Lactoferrin clearly has immunological benefits, as well as having an important antibacterial and antiviral role. Because it is known to interfere with some of the receptors used by coronaviruses, it may contribute usefully to the prevention and treatment of coronavirus infections. Figure 6 shows a possible scheme on how LF might interfere with SARS-CoV-2 binding. The binding of LF to HSPGs prevents the first contact between virus and host cells and thus prevents subsequent infection (99). HSPGs themselves are not sufficient for SARS-CoV entry. However, in SARS-CoV infections, the HSPGs play an important role in the process of cell entry (99). The anchoring sites provided by HSPGs permit initial contact between the virus and host cells and the concentration of virus particles on cell surface. SARS-CoV bound to HSPGs then rolls onto the cell membrane and scans for specific entry receptors, which leads to subsequent cell entry (99). LF enhances natural killer cell activity and stimulates neutrophil aggregation and adhesion in immune defense (135) and can restrict the entry of the virus into host cells during infection. We suggest that this process might be the same for COVID-19 (see Figure 6 for a visual representation), thereby offering useful strategies for prevention and treatment. Currently, there is also a renewed interest in ACE2 and HSPG blocking, as discussed in the introduction (5–8). LF may therefore be an excellent supplement to take, not only as a contribution to prevention but perhaps as a therapy in the event COVID-19 is diagnosed."}

LitCovid-PD-GO-BP

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T64","span":{"begin":956,"end":984},"obj":"http://purl.obolibrary.org/obo/GO_0030101"},{"id":"T65","span":{"begin":1000,"end":1022},"obj":"http://purl.obolibrary.org/obo/GO_0070488"}],"text":"Lactoferrin clearly has immunological benefits, as well as having an important antibacterial and antiviral role. Because it is known to interfere with some of the receptors used by coronaviruses, it may contribute usefully to the prevention and treatment of coronavirus infections. Figure 6 shows a possible scheme on how LF might interfere with SARS-CoV-2 binding. The binding of LF to HSPGs prevents the first contact between virus and host cells and thus prevents subsequent infection (99). HSPGs themselves are not sufficient for SARS-CoV entry. However, in SARS-CoV infections, the HSPGs play an important role in the process of cell entry (99). The anchoring sites provided by HSPGs permit initial contact between the virus and host cells and the concentration of virus particles on cell surface. SARS-CoV bound to HSPGs then rolls onto the cell membrane and scans for specific entry receptors, which leads to subsequent cell entry (99). LF enhances natural killer cell activity and stimulates neutrophil aggregation and adhesion in immune defense (135) and can restrict the entry of the virus into host cells during infection. We suggest that this process might be the same for COVID-19 (see Figure 6 for a visual representation), thereby offering useful strategies for prevention and treatment. Currently, there is also a renewed interest in ACE2 and HSPG blocking, as discussed in the introduction (5–8). LF may therefore be an excellent supplement to take, not only as a contribution to prevention but perhaps as a therapy in the event COVID-19 is diagnosed."}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T224","span":{"begin":0,"end":112},"obj":"Sentence"},{"id":"T225","span":{"begin":113,"end":281},"obj":"Sentence"},{"id":"T226","span":{"begin":282,"end":365},"obj":"Sentence"},{"id":"T227","span":{"begin":366,"end":493},"obj":"Sentence"},{"id":"T228","span":{"begin":494,"end":549},"obj":"Sentence"},{"id":"T229","span":{"begin":550,"end":650},"obj":"Sentence"},{"id":"T230","span":{"begin":651,"end":802},"obj":"Sentence"},{"id":"T231","span":{"begin":803,"end":943},"obj":"Sentence"},{"id":"T232","span":{"begin":944,"end":1133},"obj":"Sentence"},{"id":"T233","span":{"begin":1134,"end":1302},"obj":"Sentence"},{"id":"T234","span":{"begin":1303,"end":1413},"obj":"Sentence"},{"id":"T235","span":{"begin":1414,"end":1568},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Lactoferrin clearly has immunological benefits, as well as having an important antibacterial and antiviral role. Because it is known to interfere with some of the receptors used by coronaviruses, it may contribute usefully to the prevention and treatment of coronavirus infections. Figure 6 shows a possible scheme on how LF might interfere with SARS-CoV-2 binding. The binding of LF to HSPGs prevents the first contact between virus and host cells and thus prevents subsequent infection (99). HSPGs themselves are not sufficient for SARS-CoV entry. However, in SARS-CoV infections, the HSPGs play an important role in the process of cell entry (99). The anchoring sites provided by HSPGs permit initial contact between the virus and host cells and the concentration of virus particles on cell surface. SARS-CoV bound to HSPGs then rolls onto the cell membrane and scans for specific entry receptors, which leads to subsequent cell entry (99). LF enhances natural killer cell activity and stimulates neutrophil aggregation and adhesion in immune defense (135) and can restrict the entry of the virus into host cells during infection. We suggest that this process might be the same for COVID-19 (see Figure 6 for a visual representation), thereby offering useful strategies for prevention and treatment. Currently, there is also a renewed interest in ACE2 and HSPG blocking, as discussed in the introduction (5–8). LF may therefore be an excellent supplement to take, not only as a contribution to prevention but perhaps as a therapy in the event COVID-19 is diagnosed."}

MyTest

{"project":"MyTest","denotations":[{"id":"32574271-21887302-34514761","span":{"begin":489,"end":491},"obj":"21887302"},{"id":"32574271-21887302-34514762","span":{"begin":646,"end":648},"obj":"21887302"},{"id":"32574271-21887302-34514763","span":{"begin":939,"end":941},"obj":"21887302"},{"id":"32574271-15655079-34514764","span":{"begin":1055,"end":1058},"obj":"15655079"},{"id":"32574271-32228252-34514765","span":{"begin":1408,"end":1409},"obj":"32228252"},{"id":"32574271-32334062-34514765","span":{"begin":1408,"end":1409},"obj":"32334062"},{"id":"32574271-32333836-34514765","span":{"begin":1408,"end":1409},"obj":"32333836"},{"id":"32574271-32395702-34514765","span":{"begin":1408,"end":1409},"obj":"32395702"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"Lactoferrin clearly has immunological benefits, as well as having an important antibacterial and antiviral role. Because it is known to interfere with some of the receptors used by coronaviruses, it may contribute usefully to the prevention and treatment of coronavirus infections. Figure 6 shows a possible scheme on how LF might interfere with SARS-CoV-2 binding. The binding of LF to HSPGs prevents the first contact between virus and host cells and thus prevents subsequent infection (99). HSPGs themselves are not sufficient for SARS-CoV entry. However, in SARS-CoV infections, the HSPGs play an important role in the process of cell entry (99). The anchoring sites provided by HSPGs permit initial contact between the virus and host cells and the concentration of virus particles on cell surface. SARS-CoV bound to HSPGs then rolls onto the cell membrane and scans for specific entry receptors, which leads to subsequent cell entry (99). LF enhances natural killer cell activity and stimulates neutrophil aggregation and adhesion in immune defense (135) and can restrict the entry of the virus into host cells during infection. We suggest that this process might be the same for COVID-19 (see Figure 6 for a visual representation), thereby offering useful strategies for prevention and treatment. Currently, there is also a renewed interest in ACE2 and HSPG blocking, as discussed in the introduction (5–8). LF may therefore be an excellent supplement to take, not only as a contribution to prevention but perhaps as a therapy in the event COVID-19 is diagnosed."}

TEST0

{"project":"TEST0","denotations":[{"id":"32574271-123-129-2882353","span":{"begin":489,"end":491},"obj":"[\"21887302\"]"},{"id":"32574271-96-102-2882354","span":{"begin":646,"end":648},"obj":"[\"21887302\"]"},{"id":"32574271-136-142-2882355","span":{"begin":939,"end":941},"obj":"[\"21887302\"]"},{"id":"32574271-111-118-2882356","span":{"begin":1055,"end":1058},"obj":"[\"15655079\"]"},{"id":"32574271-105-110-2882357","span":{"begin":1408,"end":1409},"obj":"[\"32228252\", \"32334062\", \"32333836\", \"32395702\"]"}],"text":"Lactoferrin clearly has immunological benefits, as well as having an important antibacterial and antiviral role. Because it is known to interfere with some of the receptors used by coronaviruses, it may contribute usefully to the prevention and treatment of coronavirus infections. Figure 6 shows a possible scheme on how LF might interfere with SARS-CoV-2 binding. The binding of LF to HSPGs prevents the first contact between virus and host cells and thus prevents subsequent infection (99). HSPGs themselves are not sufficient for SARS-CoV entry. However, in SARS-CoV infections, the HSPGs play an important role in the process of cell entry (99). The anchoring sites provided by HSPGs permit initial contact between the virus and host cells and the concentration of virus particles on cell surface. SARS-CoV bound to HSPGs then rolls onto the cell membrane and scans for specific entry receptors, which leads to subsequent cell entry (99). LF enhances natural killer cell activity and stimulates neutrophil aggregation and adhesion in immune defense (135) and can restrict the entry of the virus into host cells during infection. We suggest that this process might be the same for COVID-19 (see Figure 6 for a visual representation), thereby offering useful strategies for prevention and treatment. Currently, there is also a renewed interest in ACE2 and HSPG blocking, as discussed in the introduction (5–8). LF may therefore be an excellent supplement to take, not only as a contribution to prevention but perhaps as a therapy in the event COVID-19 is diagnosed."}

2_test

{"project":"2_test","denotations":[{"id":"32574271-21887302-34514761","span":{"begin":489,"end":491},"obj":"21887302"},{"id":"32574271-21887302-34514762","span":{"begin":646,"end":648},"obj":"21887302"},{"id":"32574271-21887302-34514763","span":{"begin":939,"end":941},"obj":"21887302"},{"id":"32574271-15655079-34514764","span":{"begin":1055,"end":1058},"obj":"15655079"},{"id":"32574271-32228252-34514765","span":{"begin":1408,"end":1409},"obj":"32228252"},{"id":"32574271-32334062-34514765","span":{"begin":1408,"end":1409},"obj":"32334062"},{"id":"32574271-32333836-34514765","span":{"begin":1408,"end":1409},"obj":"32333836"},{"id":"32574271-32395702-34514765","span":{"begin":1408,"end":1409},"obj":"32395702"}],"text":"Lactoferrin clearly has immunological benefits, as well as having an important antibacterial and antiviral role. Because it is known to interfere with some of the receptors used by coronaviruses, it may contribute usefully to the prevention and treatment of coronavirus infections. Figure 6 shows a possible scheme on how LF might interfere with SARS-CoV-2 binding. The binding of LF to HSPGs prevents the first contact between virus and host cells and thus prevents subsequent infection (99). HSPGs themselves are not sufficient for SARS-CoV entry. However, in SARS-CoV infections, the HSPGs play an important role in the process of cell entry (99). The anchoring sites provided by HSPGs permit initial contact between the virus and host cells and the concentration of virus particles on cell surface. SARS-CoV bound to HSPGs then rolls onto the cell membrane and scans for specific entry receptors, which leads to subsequent cell entry (99). LF enhances natural killer cell activity and stimulates neutrophil aggregation and adhesion in immune defense (135) and can restrict the entry of the virus into host cells during infection. We suggest that this process might be the same for COVID-19 (see Figure 6 for a visual representation), thereby offering useful strategies for prevention and treatment. Currently, there is also a renewed interest in ACE2 and HSPG blocking, as discussed in the introduction (5–8). LF may therefore be an excellent supplement to take, not only as a contribution to prevention but perhaps as a therapy in the event COVID-19 is diagnosed."}

PMC:7271924 / 28556-30124 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7271924 / 28556-30124 JSON TXT